- Giving you critical information to confidently diagnose and treat Heart Failure with preserved ejection fraction (HFpEF).
EchoGo® Heart Failure
EchoGo® Heart Failure is a state-of-the-art, AI-driven solution that offers insights to assist in cardiac examinations. Our technology employs deep learning to detect HFpEF from any echocardiogram, using a single apical 4-chamber clip. We tackle the challenge of HFpEF detection, offering precise heart analysis within 30 minutes.
FDA Breakthrough Technology
The FDA cleared EchoGo® Heart Failure follows a clinical study that demonstrated its safety and efficacy. The results demonstrated excellent discrimination between patients with and without HFpEF.
We are proud to partner with the FNIH as part of The Accelerating Medicines Partnership® Heart Failure (AMP® HF), working alongside public and private sector companies, including the NIH National Heart, Lung and Blood Institute and the American Society of Echocardiography. Together, we are working to solve the complications surrounding HFpEF detection, which is crucial for the delivery of effective therapies and the improvement of patient outcomes.
Large Global Burden
Heart failure impacts 64 million worldwide, with HFpEF accounting for half of all cases [1,2,3]
No. 1 Cost of Hospitalization
$43B in 2020, increasing to $69B in 2030 [4]
High Readmission Rates and Substantial Morbidity
5 year readmission rates: 84% [5]
5 year readmission mortality rates: 75.7% [5]
Improving Diagnosis is Crucial
While transthoracic echocardiography (TTE) is routinely used to estimate intracardiac filling pressure, there is considerable variability in its performance and interpretation, imposing a heavy burden on skills, time, and expertise. Clinical algorithms have been proposed in clinical guidelines but can be hindered by discordant or incomplete information, resulting in variable diagnostic capacity and adding burden. Up to 64% of HFpEF patients may be undiagnosed. [6]
"There remains no readily available gold standard diagnostic test, with the diagnosis of HFpEF largely one of exclusion."
Emerging Therapies for HFpEF Treatment
- Strong evidencen for the use of sodium–glucose cotransporter type 2 (SGLT2) inhibitors in the treatment of HFpEF. [10, 11]
- SGLT2i Empagliflozin can reduce hospitalizations by 29% in HFpEF patients [10]
- Efficient and accurate diagnosis is needed to match patients to these new therapies.
EchoGo® Heart Failure
EchoGo® Heart Failure is designed to identify the presence or absence of HFpEF to manage patients more effectively. Disease suspicion is highlighted through reports sent to physician workstations within 30 minutes, to support smart, decisive interpretation.
Using our FDA-cleared system, our platform has helped clinicians solve indeterminate cases and has helped providers reduce costs.
of patients classified as indeterminate without EchoGo® Heart Failure
of HFpEF patients classified as indeterminate with EchoGo® Heart Failure 12
"This novel solution applies AI to cardiovascular imaging to greatly simplify the identification of HFpEF patients, a diagnosis that can be challenging, and allows more expeditious treatment."
Patricia A. Pellikka, M.D., Vice Chair, Department of Cardiovascular Medicine at Mayo Clinic
Real-world Validation
EchoGo® Heart Failure is a product of collaborative innovation, developed with the esteemed Mayo Clinic and rooted in the academic excellence of the University of Oxford. The technology has undergone rigorous real-world testing across diverse medical sites, delivering unparalleled accuracy in identifying disease. Customers include Indiana University, Northwestern University, City of Hope, and University of Wisconsin.
Reclassify >73% of non-diagnostic results
An independent study of 1,284 patients conducted by Mayo Clinic and published in JACC Advances confirmed EchoGo® HFpEF improved the classification of patients with previously non-diagnostic results when compared to HFA-PEFF and H2FPEF scores [12]
Identify high-risk patients
The diagnostic positive (HFpEF) had a 90% higher probability of dying over the 5 years. These cases have the opportunity for therapeutic intervention. [12]
EchoGo® Heart Failure is Reimbursable
- For inpatient settings, NTAP code ICD-10: XXE2X19 provides $1000 per analysis, covered by Medicare.
- In outpatient settings, HCPCS code C9786 and Clinical APC 5743 offers $284.88 per analysis.
Integrated into Your Workflow
EchoGo® embeds reports directly into your reading workflow through a secure cloud-based server:
- DICOM Secondary Capture
- DICOM SR
- EMR Integration
Interested in how EchoGo® Heart Failure integrates into your workflow?
Get in touch
We're here to showcase how our innovative solution can enhance your cardiac diagnostics. Reach out to us to learn more.